カテゴリ： DelveInsight, MOA2016, 世界, 医療/バイオ

血管内皮増殖因子A活性体のパイプライン・インサイト2016

◆英語タイトル：Vascular Endothelial Growth Factor A (VEGF-A) Activator -Pipeline Insights, 2016
◆商品コード：DIMR2016699
◆発行会社（リサーチ会社）：DelveInsight
◆発行日：2016年版（※最新版はお問い合わせください）
◆ページ数：約60
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single User（1名使用）USD1,250 ⇒換算￥136,250見積依頼/購入/質問フォーム
Site Price（同一国内共有可）USD2,500 ⇒換算￥272,500見積依頼/購入/質問フォーム
Enterprise Price（複数国内共有可）USD4,000 ⇒換算￥436,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。
本調査レポートでは、世界における血管内皮増殖因子A活性体のパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・血管内皮増殖因子A活性体の概要
・血管内皮増殖因子A活性体のパイプライン概要
・企業別開発中の血管内皮増殖因子A活性体
・後期治験段階の薬剤(Filed & Phase III)：比較分析
・中期治験段階の薬剤(Phase II)：比較分析
・初期治験段階の薬剤(Phase I & IND Filed)：比較分析
・薬剤候補のプロファイル
・血管内皮増殖因子A活性体の評価
　　- 単剤治療薬別評価
　　- 併用治療薬別評価
　　- 投与経路別評価
　　- 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・血管内皮増殖因子A活性体開発に取り組んでいる企業リスト
・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “Vascular Endothelial Growth Factor A (VEGF-A) Activator-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Vascular Endothelial Growth Factor A (VEGF-A) Activator. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Vascular Endothelial Growth Factor A (VEGF-A) Activator. DelveInsight’s Report also assesses the Vascular Endothelial Growth Factor A (VEGF-A) Activator therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of Vascular Endothelial Growth Factor A (VEGF-A) Activator
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Vascular Endothelial Growth Factor A (VEGF-A) Activator pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Vascular Endothelial Growth Factor A (VEGF-A) Activator and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Overview
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Disease Associated
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Pipeline Therapeutics
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Therapeutics under Development by Companies
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Filed and Phase III Products
• Comparative Analysis
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Phase II Products
• Comparative Analysis
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Phase I and IND Filed Products
• Comparative Analysis
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Vascular Endothelial Growth Factor A (VEGF-A) Activator – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Vascular Endothelial Growth Factor A (VEGF-A) Activator – Discontinued Products
• Vascular Endothelial Growth Factor A (VEGF-A) Activator – Dormant Products
• Companies Involved in Therapeutics Development for Vascular Endothelial Growth Factor A (VEGF-A) Activator
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Vascular Endothelial Growth Factor A (VEGF-A) Activator by Therapy Area, 2016
• Number of Products under Development for Vascular Endothelial Growth Factor A (VEGF-A) Activator, 2016
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2016
• Comparative Analysis Phase II Products, 2016
• Comparative Analysis Phase I and IND Filed Products, 2016
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
• Drug Candidates Profiles
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Monotherapy Products
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Combination Products
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Route of Administration
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Stage and Route of Administration
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Molecule Type
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Stage and Molecule Type
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Therapeutics – Discontinued Products
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Therapeutics – Dormant Products
• Products under Development by Companies, 2016


List of Figures
• Number of Products under Development for Vascular Endothelial Growth Factor A (VEGF-A) Activator by Therapy Area, 2016
• Number of Products under Development for Vascular Endothelial Growth Factor A (VEGF-A) Activator, 2016
• Filed and Phase III Products, 2016
• Phase II Products, 2016
• Phase I and IND Filed Products, 2016
• Discovery and Pre-Clinical Stage Products, 2016
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Monotherapy Products
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Combination Products
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Route of Administration
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Stage and Route of Administration
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Molecule Type
• Vascular Endothelial Growth Factor A (VEGF-A) Activator Assessment by Stage and Molecule Type


【レポートのキーワード】

血管内皮増殖因子A活性体、医薬品、製薬、研究開発、パイプライン、治療、治験

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[血管内皮増殖因子A活性体のパイプライン・インサイト2016]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. 血管内皮増殖因子D阻害剤のパイプライン・インサイト2016
    DIMR2016702 / DelveInsight / 2016年版 / 本調査レポートでは、世界における血管内皮増殖因子D阻害剤のパイプライン動向について調査・分析し、以下の構成でお届けいたします。 ・血管内皮増殖因子D阻害剤の概要 ・血管内皮増殖因子D阻害剤のパイプライン概要 ・企業別開発中の血管内皮増殖因子D阻害剤 ・後期治験段階の薬剤(Filed & Phase III)：比較分析 ・中期治験段階の薬剤(Phase II)：比較分析...SUMMARY DelveInsight’s, “Vascular Endothelial Growth Factor D (VEGF-D) Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Vascular Endothelial Growth Factor D (VEGF-D) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years...
  2. 血管内皮増殖因子C阻害剤のパイプライン・インサイト2016
    DIMR2016701 / DelveInsight / 2016年版 / 本調査レポートでは、世界における血管内皮増殖因子C阻害剤のパイプライン動向について調査・分析し、以下の構成でお届けいたします。 ・血管内皮増殖因子C阻害剤の概要 ・血管内皮増殖因子C阻害剤のパイプライン概要 ・企業別開発中の血管内皮増殖因子C阻害剤 ・後期治験段階の薬剤(Filed & Phase III)：比較分析 ・中期治験段階の薬剤(Phase II)：比較分析...SUMMARY DelveInsight’s, “Vascular Endothelial Growth Factor C (VEGF-C) Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Vascular Endothelial Growth Factor C (VEGF-C) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years...
  3. 血管内皮増殖因子B阻害剤のパイプライン・インサイト2016
    DIMR2016700 / DelveInsight / 2016年版 / 本調査レポートでは、世界における血管内皮増殖因子B阻害剤のパイプライン動向について調査・分析し、以下の構成でお届けいたします。 ・血管内皮増殖因子B阻害剤の概要 ・血管内皮増殖因子B阻害剤のパイプライン概要 ・企業別開発中の血管内皮増殖因子B阻害剤 ・後期治験段階の薬剤(Filed & Phase III)：比較分析 ・中期治験段階の薬剤(Phase II)：比較分析...SUMMARY DelveInsight’s, “Vascular Endothelial Growth Factor B (VEGF-B) Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Vascular Endothelial Growth Factor B (VEGF-B) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years...
  4. Vascular Endothelial Growth Factor A (VEGF-A) Activator：薬剤のグローバル市場2014（薬開発、治験動向）
    DIMR2014700 / DelveInsight / 2014年版 / ...DelveInsight’s,“Vascular Endothelial Growth Factor A (VEGF-A) Activator-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Vascular Endothelial Growth Factor A (VEGF-A) Activator. This report provides information on the therapeutic development based on the Vascular Endothelial Growth Factor A (VEGF-A) Activator dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule...
  5. Vascular Endothelial Growth Factor A (VEGF-A) Activator：薬剤のグローバル市場2015（薬開発、治験動向）
    DIMRMOA5700 / DelveInsight / 2015年版 / ...DelveInsight’s,“Vascular Endothelial Growth Factor A (VEGF-A) Activator-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Vascular Endothelial Growth Factor A (VEGF-A) Activator. This report provides information on the therapeutic development based on the Vascular Endothelial Growth Factor A (VEGF-A) Activator dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule...
  6. Vascular Endothelial Growth Factor D (VEGF-D) Inhibitors：阻害薬のグローバル市場2014（薬開発、治験動向）
    DIMR2014703 / DelveInsight / 2014年版 / ...DelveInsight’s,“Vascular Endothelial Growth Factor D (VEGF-D) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Vascular Endothelial Growth Factor D (VEGF-D) Inhibitors. This report provides information on the therapeutic development based on the Vascular Endothelial Growth Factor D (VEGF-D) Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule...
  7. Vascular Endothelial Growth Factor C (VEGF-C) Inhibitors：阻害薬のグローバル市場2015（薬開発、治験動向）
    DIMRMOA5702 / DelveInsight / 2015年版 / ...DelveInsight’s,“Vascular Endothelial Growth Factor C (VEGF-C) Inhibitors-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Vascular Endothelial Growth Factor C (VEGF-C) Inhibitors. This report provides information on the therapeutic development based on the Vascular Endothelial Growth Factor C (VEGF-C) Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule...
  8. Vascular Endothelial Growth Factor C (VEGF-C) Inhibitors：阻害薬のグローバル市場2014（薬開発、治験動向）
    DIMR2014702 / DelveInsight / 2014年版 / ...DelveInsight’s,“Vascular Endothelial Growth Factor C (VEGF-C) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Vascular Endothelial Growth Factor C (VEGF-C) Inhibitors. This report provides information on the therapeutic development based on the Vascular Endothelial Growth Factor C (VEGF-C) Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule...
  9. Vascular Endothelial Growth Factor B (VEGF-B) Inhibitors：阻害薬のグローバル市場2014（薬開発、治験動向）
    DIMR2014701 / DelveInsight / 2014年版 / ...DelveInsight’s,“Vascular Endothelial Growth Factor B (VEGF-B) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Vascular Endothelial Growth Factor B (VEGF-B) Inhibitors. This report provides information on the therapeutic development based on the Vascular Endothelial Growth Factor B (VEGF-B) Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule...
  10. Vascular Endothelial Growth Factor B (VEGF-B) Inhibitors：阻害薬のグローバル市場2015（薬開発、治験動向）
    DIMRMOA5701 / DelveInsight / 2015年版 / ...DelveInsight’s,“Vascular Endothelial Growth Factor B (VEGF-B) Inhibitors-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Vascular Endothelial Growth Factor B (VEGF-B) Inhibitors. This report provides information on the therapeutic development based on the Vascular Endothelial Growth Factor B (VEGF-B) Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆